Status: Recruiting
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.
Participants needed: 140
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: United Immunity, co., Ltd.Updated: Jun 3, 2026Locations: 3
Eligibility criteria
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, [+6]
central nervous system metastasis, [+9]